Work

Novel Genetic Associations in Anthracycline Cardiomyopathy (ACM) within the Pediatric Population: Scoping Review Protocol

Year: 2024

Type: report

Abstract: Anthracycline cardiomyopathy (ACM) is a well described complication following anthracycline chemotherapy – which despite this risk, remains ubiquitously used in pediatric oncology, supported by abundant data on efficacy and improved progression-free survival. Currently, there is data suggesting potential genetic drivers for the development of this cardiomyopathy, with a recent increase in ACM associated gene pathways and markers published in the last decade. To analyze the current literature and evidence on genetic markers that drive the development of this cardiomyopathy and highlight potential genetic targets, we will be completing a scoping review. The protocol for conducting this review and disseminating findings is described below.

Source: Deep Blue (University of Michigan)

DOI: 10.7302/24719

Authors: Cox, Ogochukwu M., Parnell, Nicolas, Yalavarthi, Pooja, Meisner, Joshua K., Lim, Heang, Saylor, Kate M.

Language: English

Topic: Chemotherapy-induced cardiotoxicity and mitigation

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4404749830

Cites:

Cited by:

Related to: 10